Nivolumab is a human monoclonal IgG4κ antibody against programmed cell death protein 1 (PD-1) that is FDA approved for multiple malignancies, including melanoma, non–small cell lung carcinoma, and Hodgkin’s lymphoma (17). The gene discussed is PDCD1; the disease is melanoma.